Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound to Host Third Quarter 2016 Financial Results Conference Call on November 14, 2016 at 8:30 a.m. Eastern Time
YAVNE, Israel, Nov. 04, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results for the three and nine months ended September 30, 2016, at 7:00 a.m. E...
View HTML
Toggle Summary MediWound to Present at the Credit Suisse 25th Annual Healthcare Conference
YAVNE, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Credit Suisse 25th Annual Healthcare Conference taking place from November 6...
View HTML
Toggle Summary MediWound to Present at 11th Annual Wells Fargo Healthcare Conference
YAVNE, Israel, Aug. 26, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the 11th Annual Wells Fargo Securities Healthcare Conference taking place from S...
View HTML
Toggle Summary MediWound's NexoBrid and EscharEx to be Featured at International Society for Burn Injuries 2016
Multiple oral and poster presentations highlight NexoBrid's and EscharEx' innovative, effective and fast enzymatic debriding of severe burns and chronic wounds
View HTML
Toggle Summary MediWound Reports Second Quarter 2016 Financial Results
Conference call begins today at 8:30 a.m. Eastern time
View HTML
Toggle Summary MediWound to Host Second Quarter 2016 Financial Results Conference Call on July 28, 2016 at 8:30 a.m. Eastern Time View HTML
Toggle Summary MediWound's NexoBrid® Receives Reimbursement in Italy View HTML
Toggle Summary MediWound to Present at Jefferies 2016 Healthcare Conference View HTML
Toggle Summary Data Published in Bone & Joint Research Supports MediWound's Bromelain-Based Enzyme for the Release of Dupuytren's Contracture View HTML
Toggle Summary MediWound's NexoBrid® Highlighted in "Best Oral Presentation" at the British Burn Association 49th Annual Conference and Scientific Meeting
Award-winning Abstract Underscores Role of NexoBrid in Direct Assessment of Burn Severity
View HTML